Barclays analyst Jack Meehan maintained a Hold rating on Charles River Labs (CRL) yesterday and set a price target of $135. The company’s shares closed yesterday at $139.12, close to its 52-week high of $139.91.
According to TipRanks.com, Meehan is a 4-star analyst with an average return of 5.7% and a 62.5% success rate. Meehan covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, Syneos Health Inc, and Myriad Genetics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Charles River Labs with a $141.63 average price target, a 1.8% upside from current levels. In a report released yesterday, Credit Suisse also maintained a Hold rating on the stock with a $110 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $139.91 and a one-year low of $101.58. Currently, Charles River Labs has an average volume of 384.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions.